Axsome Therapeutics (AXSM) Faces A Valuation Test Following Its CNS Growth Story

Axsome Therapeutics: recent share performance in focus

Axsome Therapeutics (AXSM) has drawn attention after a stretch of weak trading, with the stock down 7% over the past week and 26% over the past month based on provided returns.

The current share price of Axsome Therapeutics at US$144.06 reflects a sharp loss of momentum in recent months, with the 30-day share price return down 26.2% and the 90-day move weaker. However, the 3-year total shareholder return of about 140% and 5-year total shareholder return of around 263% still indicate a very strong longer term outcome.

Scan beyond Axsome Therapeutics and line up other potential rebound candidates with the hand picked 29 high quality undervalued stocks that combine quality fundamentals with compressed share prices.

Axsome Therapeutics has built a sizeable CNS portfolio, yet the share price has pulled back significantly. Is this a strong business now priced attractively, or is it still demanding a premium?

Most Popular Narrative: 49% Undervalued

Compared with Axsome Therapeutics' last close at $144.06, the most followed fair value estimate of $282.51 implies a steep valuation gap that hinges on how investors view the central nervous system portfolio scaling over the next few years.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications). This positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

See why 42 investors see Axsome Therapeutics as 49% undervalued.

Result: Fair Value of $282.51 (UNDERVALUED)

Still, that upbeat Axsome Therapeutics story leans heavily on Auvelity and Sunosi, so weaker uptake or tougher payer terms could quickly challenge the current fair value narrative.

Find out about the key risks to this Axsome Therapeutics narrative.

Another View: What Multiples Say About Axsome Therapeutics

The first fair value story for Axsome Therapeutics leans on future cash flows and long range forecasts. A quick cross check using today’s P/S ratio presents a contrasting perspective.

At about 9.7x P/S, Axsome trades above the US Pharmaceuticals average of 4.2x and above peer levels around 9.3x. Yet the fair ratio estimate of 14.4x indicates the market price may need to adjust further before fully reflecting that relationship. Is this a margin of safety, or a sign that expectations are already elevated?

See what the numbers indicate about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feels like sentiment on Axsome Therapeutics could go either way after this pullback, so move quickly, inspect the data, and decide where you stand. To see what optimistic investors are focusing on right now, take a closer look at the 3 key rewards

Looking for more Axsome Therapeutics style investment ideas?

If Axsome Therapeutics has sharpened your focus on valuation and momentum, do not stop here. Broaden your watchlist now using Simply Wall Street screeners.

• Target potential bargain opportunities before the crowd by scanning a hand picked 29 high quality undervalued stocks that pair compressed prices with stronger fundamentals.
• Strengthen your downside protection by searching through a list of solid balance sheet and fundamentals (24 results) that can help you focus on financially resilient businesses.
• Hunt for off the radar opportunities by reviewing a 21 high quality undiscovered gems that highlight quality companies still flying under most investors' radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com